The purpose of this grant application is to support Mayo Clinic membership in the North Central Cancer Treatment Group (NCCTG). Mayo Clinic at its three campuses in Rochester, Minnesota; Jacksonville, Florida; and Scottsdale, Arizona has the resources, personnel, facilities, and patient populations to facilitate strong contributions to the research programs of the NCCTG. Among NCCTG members it has the unique capability of conducting pilot studies to provide tolerability/feasibility data on regimens for NCCTG group-wide phase II and III protocols, and adjunctive correlative studies in association with NCCTG cancer treatment protocols through collaboration with laboratory investigators from the Mayo Clinic Comprehensive Cancer Center.
The specific aims of this grant proposal are to support the following aspects of Mayo Clinic participation in NCCTG research activities: 1. Patient accrual to group-wide NCCTG cancer treatment protocols 2. Pilot studies to provide background clinical data to justify group-wide NCCTG phase II and III cancer treatment protocols 3. Coordination of adjunctive laboratory-based correlative studies in association with NCCTG cancer treatment protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA025224-16
Application #
2087336
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-01-01
Project End
1996-03-31
Budget Start
1995-01-01
Budget End
1996-03-31
Support Year
16
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Zhang, Qiang; Freidlin, Boris; Korn, Edward L et al. (2017) Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials 14:48-58
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Larsen, Jeremy T; Shanafelt, Tait D; Leis, Jose F et al. (2017) Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol 92:759-763
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828

Showing the most recent 10 out of 718 publications